Mir-THYpe full can help prevent diagnostic surgeries by reclassifying the indeterminate nodule as negative (benign) or positive (malignant). This is done using molecular prognostic markers may predict a more or less aggressive behavior of the thyroid nodule.
Nodules with negative prognostic markers may be eligible for minor surgeries, such as Targeted therapies consist of drugs specifically designed to act on signaling pathways that may be altered by mutations (DNA) or by somatic fusions (RNA), directly in the tumor.
The mir-THYpe target test analyzes not only mutations (DNA) but also fusions (RNA) in 52 target genes (“drugable”), including all molecular alterations for target drug selection in Advanced Thyroid Cancer (BRAF, NTRK, ALK and RET genes) as well as allow for partial surgery, which can preserve part of the thyroid function.
